Literature DB >> 21600706

Differential antinociceptive effects of buprenorphine and methadone in the presence of HIV-gp120.

Jonathan Palma1, Alan Cowan, Ellen B Geller, Martin W Adler, Khalid Benamar.   

Abstract

BACKGROUND: We showed recently that elevated brain levels of the chemokine stromal cell-derived growth factor-1α (SDF-1α/CXCL12, a ligand for the human immunodeficiency virus [HIV] co-receptor CXCR4) diminish the antinociceptive effect of morphine, but failed to influence buprenorphine-induced antinociception. AIMS: Because the HIV-1 coat protein, glycoprotein 120 (gp120) T-tropic strain, binds to the same receptor as SDF-1α/CXCL12, the present experiments were designed to investigate the consequence of administering gp120 to rat brain on buprenorphine-induced antinociception in the 54°C hot plate test. For comparative purposes, the effect of gp120 on an equi-antinociceptive dose of methadone was also examined.
METHODS: A sterilized stainless-steel C313G guide cannula was implanted into the periaqueductal grey (PAG), a brain region critical for the processing of pain signals, and a primary site of action of many analgesics. Rats were pretreated with gp120, administered into the PAG.
RESULTS: The subsequent antinociception associated with methadone was diminished whereas buprenorphine-induced antinociception was unaffected. Buprenorphine thus appears to be a more effective analgesic than methadone in the presence of gp120 in the brain, a condition that is associated with HIV-related pain and infection. Published by Elsevier Ireland Ltd.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21600706      PMCID: PMC3925649          DOI: 10.1016/j.drugalcdep.2011.04.010

Source DB:  PubMed          Journal:  Drug Alcohol Depend        ISSN: 0376-8716            Impact factor:   4.492


  20 in total

1.  Differential effects of buprenorphine and morphine on immune and neuroendocrine functions following acute administration in the rat mesencephalon periaqueductal gray.

Authors:  R Gomez-Flores; R J Weber
Journal:  Immunopharmacology       Date:  2000-07-20

2.  Chemokines and glycoprotein120 produce pain hypersensitivity by directly exciting primary nociceptive neurons.

Authors:  S B Oh; P B Tran; S E Gillard; R W Hurley; D L Hammond; R J Miller
Journal:  J Neurosci       Date:  2001-07-15       Impact factor: 6.167

Review 3.  Are chemokines the third major system in the brain?

Authors:  Martin W Adler; Thomas J Rogers
Journal:  J Leukoc Biol       Date:  2005-10-04       Impact factor: 4.962

4.  A putative G protein-coupled receptor, RDC1, is a novel coreceptor for human and simian immunodeficiency viruses.

Authors:  N Shimizu; Y Soda; K Kanbe; H Y Liu; R Mukai; T Kitamura; H Hoshino
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

5.  Comparison of the respiratory effects of intravenous buprenorphine and fentanyl in humans and rats.

Authors:  A Dahan; A Yassen; H Bijl; R Romberg; E Sarton; L Teppema; E Olofsen; M Danhof
Journal:  Br J Anaesth       Date:  2005-04-15       Impact factor: 9.166

6.  Analgesic efficacy of buprenorphine in the presence of high levels of SDF-1α/CXCL12 in the brain.

Authors:  Khalid Benamar; Jonathan Palma; Alan Cowan; Ellen B Geller; Martin W Adler
Journal:  Drug Alcohol Depend       Date:  2010-11-26       Impact factor: 4.492

7.  Thermal hyperalgesia and mechanical allodynia produced by intrathecal administration of the human immunodeficiency virus-1 (HIV-1) envelope glycoprotein, gp120.

Authors:  E D Milligan; K K Mehmert; J L Hinde; L O Harvey; D Martin; K J Tracey; S F Maier; L R Watkins
Journal:  Brain Res       Date:  2000-04-07       Impact factor: 3.252

Review 8.  Current knowledge of buprenorphine and its unique pharmacological profile.

Authors:  Joseph Pergolizzi; Anna Maria Aloisi; Albert Dahan; Joerg Filitz; Richard Langford; Rudolf Likar; Sebastiano Mercadante; Bart Morlion; Robert B Raffa; Rainer Sabatowski; Paola Sacerdote; Luis M Torres; Avi A Weinbroum
Journal:  Pain Pract       Date:  2010 Sep-Oct       Impact factor: 3.183

9.  Buprenorphine ameliorates the effect of surgery on hypothalamus-pituitary-adrenal axis, natural killer cell activity and metastatic colonization in rats in comparison with morphine or fentanyl treatment.

Authors:  Silvia Franchi; Alberto E Panerai; Paola Sacerdote
Journal:  Brain Behav Immun       Date:  2007-02-08       Impact factor: 7.217

10.  Buprenorphine and methadone maintenance treatment of heroin addicts preserves immune function.

Authors:  Paola Sacerdote; Silvia Franchi; Gilberto Gerra; Vincenzo Leccese; Alberto E Panerai; Lorenzo Somaini
Journal:  Brain Behav Immun       Date:  2008-02-21       Impact factor: 7.217

View more
  3 in total

1.  Morphine efficacy is altered in conditional HIV-1 Tat transgenic mice.

Authors:  Sylvia Fitting; Krista L Scoggins; Ruqiang Xu; Seth M Dever; Pamela E Knapp; William L Dewey; Kurt F Hauser
Journal:  Eur J Pharmacol       Date:  2012-05-30       Impact factor: 4.432

2.  HIV-gp120 and physical dependence to buprenorphine.

Authors:  J Palma; M E Abood; K Benamar
Journal:  Drug Alcohol Depend       Date:  2015-02-26       Impact factor: 4.492

Review 3.  2017 HIVMA of IDSA Clinical Practice Guideline for the Management of Chronic Pain in Patients Living With HIV.

Authors:  R Douglas Bruce; Jessica Merlin; Paula J Lum; Ebtesam Ahmed; Carla Alexander; Amanda H Corbett; Kathleen Foley; Kate Leonard; Glenn Jordan Treisman; Peter Selwyn
Journal:  Clin Infect Dis       Date:  2017-10-30       Impact factor: 9.079

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.